Mosby's 2023 Nursing Drug Reference (Skidmore Nursing Drug Reference)
Type
Book
Authors
ISBN 10
0323930727
ISBN 13
9780323930727
Category
Nursing
[ Browse Items ]
Publication Year
2023
Publisher
Pages
1504
Subject
Drugs -- Handbooks, manuals, etc Nursing -- Handbooks, manuals, etc Pharmacology Drugs -- Dosage Pharmaceutical Preparations -- administration & dosage Pharmacology
Tags
Abstract
Choose the drug handbook trusted by nurses for more than 35 years! Mosby's 2023 Nursing Drug Reference makes it easy to find the most vital information on the drugs you administer most frequently. More than 5,000 drugs are profiled -- including 35 new entries for drugs recently approved by the FDA. And no other drug guide places a higher emphasis on patient safety, with Black Box Warnings for dangerous adverse reactions, Safety Alerts for situations requiring special attention, and a focus on both common and life-threatening side effects. From nursing pharmacology expert Linda Skidmore-Roth, this perennial bestseller proves there is a difference in drug guides.--From publisher description
Description
x, 1490 pages (5 unnumbered pages) ; 19 cm
Biblio Notes
Includes index
Contents Individual drug monographs -- Appendixes: A. Selected new drugs:abametapir ; aducanumab-avwa ; afamelanotide ; anifrolumab-fnia ; asciminib ; atogepant ; avacopan ; avapritinib ; belumosudil ; belzutifan ; bempedoic acid ; brolucizumab-dbll ; difelikefalin ; dostarlimab-gxly - eculizumab ; efavirenz/emtricitabine/tenofovir ; elapegademase-ivir ; elbasvir/grazoprevir ; elexacaftor/tezacaftor/ivacaftor and ivacaftor ; emtricitabine/rilpivirine/tenofovir alafenamide ; enalapril/hydrochlorothiazide ; ephedrine ; factor IX, complex ; factor IX, human ; factor IX, recombinant ; finerenone ; fluocinolone ; fluocinonide ; lonapegsomatropin-tcgd ; loncastuximab tesirine-lpyl ; maribavir ; mobocertinib ; odevixibat ; ropeginterferon alfa-2b ; tisotumab vedotin-tfv ; vosoritide -- B. Ophthalmic, nasal, topical, and otic products -- C. Vaccines and toxoids -- D. Recent FDA drug approvals
Contents Individual drug monographs -- Appendixes: A. Selected new drugs:abametapir ; aducanumab-avwa ; afamelanotide ; anifrolumab-fnia ; asciminib ; atogepant ; avacopan ; avapritinib ; belumosudil ; belzutifan ; bempedoic acid ; brolucizumab-dbll ; difelikefalin ; dostarlimab-gxly - eculizumab ; efavirenz/emtricitabine/tenofovir ; elapegademase-ivir ; elbasvir/grazoprevir ; elexacaftor/tezacaftor/ivacaftor and ivacaftor ; emtricitabine/rilpivirine/tenofovir alafenamide ; enalapril/hydrochlorothiazide ; ephedrine ; factor IX, complex ; factor IX, human ; factor IX, recombinant ; finerenone ; fluocinolone ; fluocinonide ; lonapegsomatropin-tcgd ; loncastuximab tesirine-lpyl ; maribavir ; mobocertinib ; odevixibat ; ropeginterferon alfa-2b ; tisotumab vedotin-tfv ; vosoritide -- B. Ophthalmic, nasal, topical, and otic products -- C. Vaccines and toxoids -- D. Recent FDA drug approvals
Number of Copies
1